HRT Financial’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-7,171
Closed -$281K 3507
2024
Q4
$281K Sell
7,171
-22,470
-76% -$929K ﹤0.01% 1754
2024
Q3
$1.17M Sell
29,641
-4,551
-13% -$183K 0.01% 1163
2024
Q2
$1.33M Buy
34,192
+1,584
+5% +$63.3K 0.01% 888
2024
Q1
$1.4M Sell
32,608
-50,461
-61% -$2.32M 0.01% 724
2023
Q4
$3.83M Buy
83,069
+47,859
+136% +$1.69M 0.03% 394
2023
Q3
$1.2M Buy
35,210
+17,264
+96% +$646K 0.01% 876
2023
Q2
$690K Buy
+17,946
New +$713K 0.01% 1179
2022
Q4
Sell
-15,927
Closed -$574K 3267
2022
Q3
$574K Sell
15,927
-3,975
-20% -$143K 0.01% 1346
2022
Q2
$605K Buy
+19,902
New +$602K 0.01% 1349
2021
Q4
Sell
-10,357
Closed -$158K 4200
2021
Q3
$158K Sell
10,357
-8,297
-44% -$144K ﹤0.01% 2766
2021
Q2
$347K Sell
18,654
-2,224
-11% -$41K ﹤0.01% 2054
2021
Q1
$373K Buy
+20,878
New +$354K ﹤0.01% 1984
2020
Q1
Sell
-18,220
Closed -$238K 1428
2019
Q4
$238K Buy
+18,220
New +$192K 0.01% 862

Other funds holding XENE

HRT Financial's XENE Position: Q1 2025 in Review

HRT Financial sold out of Xenon Pharmaceuticals (XENE) in Q1 2025, closing a stake of 7,171 shares — an estimated $281K sold.

HRT Financial first reported a position in XENE in Q4 2019 and held it in 13 quarters. The position peaked at $3.83M in Q4 2023. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

  • HRT Financial reported no remaining Xenon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 7,171 Xenon Pharmaceuticals shares in Q1 2025, an estimated $281K.
  • HRT Financial first reported a position in Xenon Pharmaceuticals in Q4 2019 and held it in 13 quarters.
  • HRT Financial's Xenon Pharmaceuticals position peaked at $3.83M in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.